Hookworm Vaccine Trials Begin at GW

In a pioneering study, infecting healthy adults is the next step toward eradicating the infection. “These past few months have taught me a lot about hookworms, and it’s also given me intriguing insight into my own body and behaviors,” she said. Ms. Markowitz is one of the participants of the Hookworm Study. Check out this article to read more about Ms. Markowitz's experience.

 

Latest News

This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…